About Us

Nebulabio is a specialized mammalian cell line engineering team focused on building high-performance CHO production cell lines for therapeutic proteins and monoclonal antibodies. Our work integrates expression cassette design, productivity-driven selection, single-cell cloning with monoclonality evidence, and deep clone characterization to deliver cell lines that perform reliably in manufacturing-relevant fed-batch conditions. 

☞Nebulabio High-performance CHO Platform

Our platform is built to compress timelines while improving the probability of finding an elite, stable producer. We combine host routing (CHO-K1/CHO-S/CHO-DG44/GS−/DHFR−), expression architecture selection (GS, DHFR, or site-specific integration), and high-throughput clone screening that evaluates productivity together with early quality indicators (aggregation risk, charge heterogeneity, and glycan directionality). The output is a traceable, bankable clone with defined performance and documented evidence.

☞Supported Options

☞Principle of High-performance CHO Cell Line Development

High-performance CHO cell line development establishes a heritable production chassis by integrating an expression cassette into the CHO genome and selecting clones that maintain productivity and quality over manufacturing-relevant timeframes. The workflow starts with an expression architecture that balances transcriptional strength with stability (promoter/enhancer choice, UTR/intron design, selection marker strategy). Following transfection, selective pressure enriches for stable integrants. Single-cell cloning isolates genetically homogeneous lines, and high-throughput screening rank-orders clones by titer, specific productivity, growth behavior, and early product quality signals. Lead clones then undergo extended stability evaluation (typically dozens of generations without selection) to confirm sustained expression and consistent quality attributes. A final production clone is expanded, banked, and released with traceable documentation.

☞Nebulabio Service Workflow

☞Featured Applications

■ Monoclonal Antibody Therapeutics (IgG1/IgG4, bispecific candidates)

High-performance CHO clones provide the consistency required for candidate progression from discovery lots to IND-enabling and early clinical supply. Stable expression supports lot-to-lot comparability, while early quality snapshots (aggregation tendency, charge profile, and glycan directionality) reduce the risk of late-stage reformulation or re-cloning.

■ Fc-fusion Proteins, Cytokines, and Secreted Enzymes

Many secreted biologics are limited by folding efficiency, disulfide formation, and secretion bottlenecks rather than transcription alone. CHO remains a practical chassis for these formats because secretion and glycosylation pathways can be balanced through construct design and clone selection. This is particularly relevant for Fc-fusions where glycan control affects effector function and PK, and for cytokines/enzymes where stability and aggregation sensitivity demand a carefully screened producer.

■ Biosimilar and Biobetter Development

For biosimilars, the development goal is not only titer but also alignment to a target product profile: charge variants, N-glycan distribution, and aggregate levels must remain within defined windows. Clone ranking that integrates productivity with early CQA indicators helps converge faster on clones that can support analytical comparability packages.

■ Platform-ready Supply for Process Development and Tech Transfer

Well-characterized CHO production clones enable process development teams to lock upstream parameters (media/feed strategy, culture duration, harvest criteria) earlier, with confidence that expression will remain stable across passages and scale. This accelerates transfer to internal manufacturing or CMOs and supports documentation needs for regulatory submissions.